Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
(2014) Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics — Vol. 16, n° 10, p. 1016-1027 (2014)
Files
Yale_et_al-2014-Diabetes_Obesity_and_Metabolism.pdf
Restricted Access - Adobe PDF
- 801.21 KB
Details
- Authors
- Affiliations
Citations
Yale, J.-F., Bakris, G., Cariou, B., Nieto, J., David-Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., Usiskin, K., Meininger, G., & DIA3004 Study Group. (2014). Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 16(10), 1016-1027. https://doi.org/10.1111/dom.12348 (Original work published 2014)